Trevi Therapeutics, Inc. Proceeds from Issuance of Private Placement
Trevi Therapeutics, Inc. (TRVI) reported Proceeds from Issuance of Private Placement of $105.41 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2024-03-20
- Trevi Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2022-12-31 was $2.40M.
- Trevi Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2022-09-30 was $51.18M.
- Trevi Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2019-12-31 was $0.00.
- Trevi Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2019-09-30 was $0.00.
- Trevi Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2022 was $105.41M, a 670.65% increase from fiscal 2021.
- Trevi Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2021 was $13.68M.
- Trevi Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2019 was $13.95M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2022-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $53.58M derived: sum of 2 quarters · filed 2024-03-20 | $105.41M 10-K · filed 2024-03-20 | |
| 2022-09-30 | $51.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $103.01M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $51.83M 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $13.68M 10-K · filed 2023-03-16 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $13.95M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $13.95M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $13.95M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |